Click on image to view ad details and full-size version on AdPharm.

To see all of this brand’s ads on AdPharm, click here

Click on image to view ad details and full-size version on AdPharm

To see all of this brand’s ads on AdPharm, click here

Click on thumbnail to view the full-size ad on AdPharm

Introducing Simponi.
The first monthly SC anti TNF a…

… all in one

-Proven efficacy in RA, As and PsA
-SmartJect autoinjector – designed to be patient-friendly
-Low injection volume (0.5 mL)
-Human lgG1k monoclonal antibody
-Patient support through the BioAdvantage Network

Monthly Simponi

The Simponi SmartJect autoinjector. Designed to be arthritis-patient-friendly.

Brand name: Simponi
Generic name/category: Golimumab, Monoclonal antibodies, TNF-alpha inhibitors
Company: Schering-Plough
Country/Market: Canada, North America
Indication(s)/use: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondilitis (AS)
Target: Healthcare Professionals (HCP)
Tagline: all in one
Medium: Print ad
Size/duration: three-page spread
Publication/Aired: NEJM – September 24, 2009

To see all of this brand’s ads on AdPharm, click here

In moderate to severe Crohn’s disease, demonstrated to sustain power, sustain remission.

Adalimumab (brand name HUMIRA) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFa, preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFa inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. As of 2008 adalimumab has been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

Humira (brand name is an abbreviation of "Human Monoclonal Antibody in Rheumatoid Arthritis") is marketed in both preloaded 0.8 ml syringes and also in preloaded pen devices (called Humira Pen), both injected subcutaneously, typically by the patient at home. It cannot be administered orally, because the digestive system would destroy the drug.

Humira’s manufacturer is Abbott Laboratories. – Wikipedia

CMAJ April 2009

More Humira ads on AdPharm